Tony A. Muller

Hugstetter Str. 55
Freiburg, BW 79106, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.

Journal: HemaSphere
Published: October 27, 2025

Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies.

Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies.

Journal: Signal transduction and targeted therapy
Published: April 10, 2025

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling.

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling.

Journal: Nature communications
Published: June 24, 2024

The role of inflammasomes as central inflammatory hubs in Mycobacterium tuberculosis infection.

The role of inflammasomes as central inflammatory hubs in Mycobacterium tuberculosis infection.

Journal: Frontiers in immunology
Published: May 22, 2024

Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression.

Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression.

Journal: Nature communications
Published: November 15, 2023

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.

Journal: Blood
Published: October 12, 2023

A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.

A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.

Journal: Molecular oncology
Published: July 25, 2023

Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.

Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.

Journal: The Journal of clinical investigation
Published: January 04, 2023

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.

Journal: Blood
Published: May 27, 2022

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis.

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis.

Journal: Frontiers in oncology
Published: February 13, 2022

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.

Journal: Blood
Published: January 12, 2022

Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR.

Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR.

Journal: International journal of molecular sciences
Published: September 16, 2021
Showing 1-12 of 20

Last Updated: 09/26/2026